 |
|
 |
 |
|
||||||||||||||
|
Taranabant is the official name of Merck’s MK-0364 April 3, 2007 Sanofi’s diet drug Rimonabant (Acomplia / Zimulti), which is seeking clearance from the FDA, has got a competitor in “Taranabant”-- official generic name for Merck's MK-0364. The drug is in its phase III trials. According to reports, Taranabant is Merck's cannabinoid-1 (CB-1) receptor inverse agonist and is as effective for weight loss as Rimonabant, with fewer side effects. However, Merck has said the pill was well tolerated in extensive phase II trials and that it plans to seek FDA’s nod for Taranabant next year. Pfizer has not come out with a name for its diet drug, which, as of now is known as CP-945598. It is also a CB-1 receptor antagonist currently in its phase III trials. Come June and both Merck and Pfizer will be eagerly watching the
outcome of the FDA advisory panel meeting on Rimonabant,
which is expected to focus mainly on its safety issues. |
||||||||||||||
